Recent Patents on Anti-Cancer Drug Discovery

Recent Patents on Anti-Cancer Drug Discovery is a quarterly title from Bentham Science Publishers in Sharjah, published since 2006 and indexed in MEDLINE from its first issue. Reviews of patented anticancer agents share the pages with research that tests those patents, and the 2025 Journal Impact Factor stands at 2.4.《抗癌药物发现最新专利》是 Bentham Science Publishers 在沙迦出版的季刊，2006 年创刊，自首期起被 MEDLINE 收录。已获专利的抗癌药物综述与检验这些专利的研究同处一册，2025 年期刊影响因子为 2.4。

Scope

• Editorial policy begins with the patent, so a paper is expected to address a granted claim or a published application, and the disease category alone will not carry a proposal.编辑方针以专利为起点，论文要对准一项已授权的权利要求或已公开的申请，仅凭疾病类别不足以支撑选题。

• A second accepted form takes a patent already on the register and reports how it behaved when applied in a new experimental setting.另一种被接受的形式取一项已登记的专利，报告它在新实验环境中应用时的表现。

• Comparative accounts belong here as well, particularly where two patented routes to the same target are measured side by side.对比性论述同样在列，尤其是把通往同一靶点的两条专利路线并置衡量的稿件。

• Guest editors assemble thematic issues around one compound class, one target family or one therapeutic modality, drawing the recent patent record into a single bundle.客座编辑围绕一个化合物类别、一个靶点家族或一种治疗模式组织主题专刊，把近期专利记录收进同一束中。

• Novel bioactive compounds occupy the largest single block, and natural products with cytotoxic or chemosensitising activity appear with some regularity.新型生物活性化合物占据最大的一块版面，具有细胞毒性或化学增敏活性的天然产物也时常出现。

• Medicinal chemistry follows close behind, covering synthetic routes and structure-activity series, with a further strand rebuilding analogues on scaffolds that already carry patent protection.药物化学紧随其后，合成路线与构效关系系列都在其中，另有一类工作是在已受专利保护的骨架上重建类似物。

• Target discovery enters through kinases and nuclear receptors, while apoptotic regulators and angiogenic signalling each get their patent position set out.靶点发现涵盖激酶与核受体等成熟方向，凋亡调控与血管生成信号的专利格局亦逐类梳理。

• Screening platforms and assay technologies protected by patent get their own space, since an assay can be the commercially decisive claim in a programme.受专利保护的筛选平台与检测技术单列一类，检测方法本身常常就是项目里最具商业分量的权利要求。

• Predictive biomarkers receive explicit attention, above all markers that would separate a trial population before treatment begins.预测性生物标志物受到明确关注，首要的是能在治疗开始前区分试验人群的标记物。

• Efficacy biomarkers sit beside them, asking how response or resistance might be read early enough to change a regimen.疗效生物标志物与之并列，考察反应或耐药能否被足够早地读出，以便调整用药方案。

• Immunotherapy and gene therapy enter through combinations, where a patented agent sensitises tumours to radiotherapy or to conventional cytotoxic drugs.免疫治疗与基因治疗经由联合方案进入，专利药物在此提高肿瘤对放疗或常规细胞毒药物的敏感性。

• Delivery forms a recurring subject, running from formulation patents to the lipid nanoparticles and messenger RNA vectors covered in recent reviews.递送是反复出现的主题，从制剂专利一直延伸到近期综述涉及的脂质纳米粒与信使 RNA 载体。

• Transporter-mediated multidrug resistance, and the natural products tested against it, has been reviewed within these pages.转运体介导的多药耐药以及针对它的天然产物测试，本刊已刊出专门综述。

• Fast-emerging therapeutic areas count wherever patents have been filed, so coverage tracks the filing record instead of following fashion.申报活跃的新兴治疗领域同样纳入，覆盖范围跟随申报记录而非一时风潮。

• Book reviews of e-books and monographs appear from time to time, shorter than the review articles and free of the patent comparison that governs the rest.电子书与专著的短评间或出现，篇幅短于综述正文，不必承担其余栏目那样的专利比对。

• Each issue closes with a selection of important recent patents, annotated so that a reader can see what was claimed and by whom.每期结尾附一组重要近期专利选目，附注说明权利要求的内容与申请人。

History

• Volume 1, number 1 carries a January 2006 date, and the imprint names Bentham Science Publishers of Sharjah in the United Arab Emirates.第 1 卷第 1 期标注 2006 年 1 月，版权页署名为阿拉伯联合酋长国沙迦的 Bentham Science Publishers。

• The house had built a family of titles on the Recent Patents on ... formula, covering biotechnology, nanotechnology and drug delivery among other fields.这家出版社以“Recent Patents on …”为范式建起一批刊物，生物技术与药物递送即在其列。

• Reviews of angiogenesis patents appeared in that first volume, together with long pieces on platinum complexes and on inhibitors of apoptosis.首卷刊有血管生成专利的综述，另有铂类配合物与凋亡抑制剂的长文。^[1]

• MEDLINE and PubMed have taken the journal from volume 1, number 1, and Science Citation Index Expanded lists it under the abbreviation RECENT PAT ANTI-CANC.MEDLINE 与 PubMed 自第 1 卷第 1 期起收录本刊，Science Citation Index Expanded 以 RECENT PAT ANTI-CANC 为缩写著录。

• Crossref records three numbers in each volume from 1 to 10, so the first decade ran to three issues a year.Crossref 记录显示第 1 卷至第 10 卷每卷三期，最初十年因此每年出三期。

• Volume 11, dated 2016, was the first to carry four issues, the rhythm the National Library of Medicine still records for the title.第 11 卷（2016 年）首次排满四期，美国国立医学图书馆至今仍按四期一年著录。

• One volume has appeared in each year since the launch, and the sequence now stands at 21.自创刊起每年出版一卷，卷号现已排到第 21 卷。

• Print copies carry 1574-8928 and the electronic edition 2212-3970, both numbers still in force.印本刊号为 1574-8928，电子版使用 2212-3970，两个号码至今有效。

• Impact factors have moved inside a narrow band, at 3.038 in 2022, 2.5 in 2023, a peak of 4.1 in 2024 and 2.4 in 2025.影响因子在窄带内起伏，2022 年为 3.038，2023 年为 2.5，2024 年升至 4.1，2025 年回落到 2.4。

• The five-year figure is 2.7 and the Journal Citation Indicator 0.59, which places the title in the third quartile of oncology and of pharmacology alike.五年影响因子为 2.7，期刊引文指标为 0.59，刊物在肿瘤学与药学两个类目中都落在第三四分位。

• In the 2025 release it ranks 214 of 333 titles in oncology and 215 of 356 in pharmacology and pharmacy.2025 年版排名中，肿瘤学一栏列 333 种期刊的第 214 位，药理学与药学一栏列 356 种的第 215 位。

• Output stays modest at 29 articles in the latest JCR year, while total citations reach 1,217 and the cited half-life runs to 4.9 years.年发文量不大，JCR 最新年度为 29 篇，总被引达 1217 次，被引半衰期为 4.9 年。

• Gold open access accounts for 7.02 percent of recent papers, so subscription remains the main route to the text.金色开放获取占近年论文的 7.02%，订阅仍是获取全文的主要途径。

• Neither NLM nor Crossref records a former title, and the name has stood unchanged for twenty years.NLM 与 Crossref 的记录里都没有旧刊名，刊名二十年未改。

• Article identifiers sit under the 10.2174 prefix that Crossref registers to the house, so the whole run resolves through one publisher namespace.文章标识符落在 Crossref 分配给这家出版社的 10.2174 前缀之下，全刊由此共用同一个出版方命名空间。

• Book reviews tie the journal to Bentham's ebook list, where series such as Frontiers in Anti-Cancer Drug Discovery carry the same subject matter.书评把刊物与 Bentham 的电子书书目连在一起，Frontiers in Anti-Cancer Drug Discovery 这类丛书处理的是同一片题材。

Editors

• Zhe-Sheng Chen, professor of pharmaceutical sciences at St. John's University in Queens, New York, holds the editorship.主编为（Zhe-Sheng Chen），纽约皇后区圣约翰大学药学系教授。

• His laboratory works on ATP-binding cassette transporters and the multidrug resistance they confer, a subject the journal returns to often.其实验室研究 ATP 结合盒转运体以及由此形成的多药耐药，本刊反复回到这一主题。

• He edits Drug Resistance Updates as well, which keeps the two titles in conversation about resistance mechanisms.他同时主编 Drug Resistance Updates，两份刊物在耐药机制上彼此呼应。

• Signed prefaces carry his name at the front of recent volumes, among them the opening issue of volume 16 in 2021.近年卷次的卷首前言由他署名，2021 年第 16 卷第 1 期即为一例。^[2]

• Work from his group has appeared in the journal too, including a 2021 review of natural products that act as transporter substrates.其课题组的成果也见诸本刊，2021 年一篇关于天然产物作为转运体底物的综述即属此列。^[3]

• Thematic issues carry guest editors, invited for their expertise in the compound class or the target under examination.主题专刊另设客座编辑，人选依所讨论的化合物类别或靶点专长确定。

• Manuscripts arrive through Bentham's online submission system, where review articles and shorter research papers follow separate templates.稿件经 Bentham 的在线投稿系统进入，综述与较短的研究论文各用一套模板。

• Book reviews and the patent selection are short standing slots, set beside the main reviews rather than among them.书评与专利选目是篇幅不长的常设栏目，排在主要综述之侧而非其中。

• Outside referees report on each paper before the editor decides, and revision is the usual route to acceptance.每篇论文先由外部审稿人出具意见，再由主编定夺，修回通常是通向录用的常规路径。

• Correspondence runs through the Sharjah office that NLM records for the title, with a San Francisco address listed in the early volumes.通讯往来经沙迦办公室处理，这也是 NLM 记录的刊址，早期卷次还并列过旧金山地址。